All Stories

  1. Dietary patterns and lupus—a new piece in an unfinished puzzle
  2. Risk of ischaemic and non-ischaemic heart failure in patients with systemic sclerosis: a population-based study
  3. Thiopurines and Intrahepatic Cholestasis of Pregnancy in Systemic Lupus Erythematosus and Inflammatory Bowel Disease Pregnancies
  4. Smoking and the risk of sarcoidosis: a systematic review and meta-analysis
  5. Temporal trends in glucocorticoids and hydroxychloroquine for treatment of systemic lupus erythematosus in Sweden
  6. Sarcoidosis Treatment Patterns in the United States
  7. GWAS identifies genetic loci, lifestyle factors and circulating biomarkers that are risk factors for sarcoidosis
  8. Development and evaluation of a Register-Based Organ Damage Index in systemic lupus erythematosus: a nationwide, population-based study from Sweden
  9. Menopausal hormone therapy and the risk of systemic lupus erythematosus and systemic sclerosis: a population-based nested case-control study
  10. Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden
  11. Response
  12. Association between maternal systemic lupus erythematosus and infant infection: a population-based cohort study in Sweden
  13. History and Familial Aggregation of Immune-Mediated Diseases in Sarcoidosis
  14. Predicting the risk of pulmonary deterioration in sarcoidosis
  15. Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case–control study in Sweden
  16. Anti-SARS-CoV-2 mRNA vaccination among patients living with SLE in Sweden: Coverage and clinical effectiveness
  17. Sick leave and disability pension following delivery in women with systemic lupus erythematosus
  18. Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
  19. Menopausal hormone therapy and risk of sarcoidosis: a population-based nested case–control study in Sweden
  20. Sarcoidosis and its relation to other immune-mediated diseases: Epidemiological insights
  21. “The chameleon among diseases” - an explorative view of sarcoidosis and identification of the consequences for affected patients and relatives using qualitative interviews
  22. Epidemiology and Damage Accrual of Systemic Lupus Erythematosus in Central Sweden: A Single‐Center Population‐Based Cohort Study Over 14 Years From Östergötland County
  23. Rheumatoid arthritis and the risk of postpartum psychiatric disorders: a Nordic population-based cohort study
  24. Sarcoidosis: Epidemiology and clinical insights
  25. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers
  26. Modifiable lifestyle risk factors for sarcoidosis: a nested case–control study
  27. Risk of gestational diabetes mellitus in relation to early pregnancy and gestational weight gain before diagnosis: A population‐based cohort study
  28. Direct modeling of relative and absolute risks in register data: Mortality risk in sarcoidosis
  29. Reproductive and hormonal risk factors for sarcoidosis: a nested case–control study
  30. Differences in disease presentation between men and women with sarcoidosis: A cohort study
  31. Gestational Diabetes Mellitus Risk in Pregnant Women With Systemic Lupus Erythematosus
  32. Risk of acute myocardial infarction in sarcoidosis: A population-based cohort study from Sweden
  33. Infection hospitalisation in systemic lupus in Sweden
  34. Risk and predictors of heart failure in sarcoidosis in a population-based cohort study from Sweden
  35. Evidence of under‐reporting of early‐onset preeclampsia using register data
  36. Type 2 diabetes risk in sarcoidosis patients untreated and treated with corticosteroids
  37. Tuberculosis in Biologic-naïve Patients With Rheumatoid Arthritis: Risk Factors and Tuberculosis Characteristics
  38. Maternal Hypertensive Disorders in Pregnant Women With Systemic Lupus Erythematosus and Future Cardiovascular Outcomes
  39. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis
  40. Positive Predictive Value of Sarcoidosis Identified in an Administrative Healthcare Registry: A Validation Study
  41. Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective ‘target trial’ emulated with Swedish real‐world data
  42. Maternal and infant outcomes in sarcoidosis pregnancy: a Swedish population-based cohort study of first births
  43. Gestational weight gain and delivery outcomes: A population‐based cohort study
  44. Sarcoidosis epidemiology: recent estimates of incidence, prevalence and risk factors
  45. Response to: ‘Neuroinflammatory events after anti-TNFα therapy’ by Kaltsonoudiset al
  46. Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study
  47. Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden
  48. Are infectious diseases risk factors for sarcoidosis or a result of reverse causation? Findings from a population-based nested case–control study
  49. Sarcoidosis diagnosis and treatment in Sweden: A register-based assessment of variations by region and calendar period
  50. Sarcoidosis
  51. The Risk of Ischemic and Hemorrhagic Stroke in Patients With Idiopathic Inflammatory Myopathies: A Swedish Population‐Based Cohort Study
  52. Correspondence for “Clinical epidemiology of familial sarcoidosis: A systematic literature review”
  53. Infections increase the risk of developing Sjögren's syndrome
  54. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden
  55. Work ability before and after sarcoidosis diagnosis in Sweden
  56. Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study
  57. Epidemiology of sarcoidosis: current findings and future directions
  58. Children born to mothers with lupus are at a higher risk for childhood asthma
  59. Dr. Rossides, et al reply
  60. Sarcoidosis: Family history is a very strong risk factor – 39% of disease risk due to genetics
  61. Childhood death rates declined in Sweden from 2000 to 2014 but deaths from external causes were not always investigated
  62. Mortality is low for the majority of individuals with sarcoidosis
  63. Response to: ‘Increased stroke incidence in systemic lupus erythematosus patients: risk factors or disease itself?’ by Bruzzese and Zullo
  64. Higher mortality and lower functionality after stroke for patients with systemic lupus erythematosus
  65. Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case–control study
  66. Elevated BMI and antibodies to citrullinated proteins interact to increase rheumatoid arthritis risk and shorten time to diagnosis: A nested case–control study of women in the Nursesʼ Health Studies
  67. Stroke in systemic lupus erythematosus: a Swedish population-based cohort study
  68. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study
  69. Cervical neoplasia in systemic lupus erythematosus: a nationwide study
  70. Medication use among pregnant women with systemic lupus erythematosus and general population comparators
  71. Early-onset Preeclampsia in Lupus Pregnancy
  72. Brief Report: Sex Ratio of Offspring Born to Women With Systemic Lupus Erythematosus or Rheumatoid Arthritis
  73. Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
  74. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden
  75. What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population‐Based Study of Maternal and Fetal Outcomes in SLE and Pre‐SLE
  76. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers
  77. Endometriosis and systemic lupus erythematosus: a population-based case–control study
  78. Case definitions in Swedish register data to identify systemic lupus erythematosus
  79. Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies
  80. Cohort profile: systemic lupus erythematosus in Sweden: the Swedish Lupus Linkage (SLINK) cohort: Figure 1
  81. Monocyte chemotactic protein-1 elevation prior to the onset of rheumatoid arthritis among women
  82. Perinatal risk factors for future SLE: a population-based nested case-control study
  83. No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment
  84. Circulating 25-hydroxyvitamin D level and risk of developing rheumatoid arthritis
  85. Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study
  86. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
  87. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
  88. Patients With Ulcerative Colitis Miss More Days of Work Than the General Population, Even Following Colectomy
  89. Exposure to ultraviolet-B and risk of developing rheumatoid arthritis among women in the Nurses’ Health Study
  90. Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case–control study
  91. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study
  92. Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study
  93. Ten years with biologics: to whom do data on effectiveness and safety apply?
  94. Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers
  95. A Prospective Study of Periodontal Disease and Risk of Rheumatoid Arthritis
  96. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission